U.S. License Holder:
Accord BioPharma Inc.
Date of License:
October-10-2024
Last Update:
Nov-15-2024
FDA-Approved Indications
IMULDOSA (ustekinumab-srlf) is a human interleukin -12 and -23 antagonist indicated for the treatment of:
Adult patients with:
Moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy;
Active psoriatic arthritis (PsA);
Moderately to severely active Crohn's disease (CD);
Moderately to severely active ulcerative colitis.
Pediatric patients 6 years and older with:
Moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy;
Active psoriatic arthritis (PsA).
